FIELD: medicine, pharmaceutics.
SUBSTANCE: what is offered is application of O-(3-piperidino-2-hydroxy-1-propyl)-nicotinamidoxime (also known as BGP-15) or its pharmaceutically acceptable acid addition salts for preventing abnormal body weight gain or obesity. The other insulin sensibilisers (metformin, rosiglitazone) showed no such action.
EFFECT: BGP-15 prevents weight gain caused by the neuroleptics olanzapine and clozapine.
4 cl, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION POSSESSING ANTIPSYCHOTIC, ANTIDEPRESSANT AND ANTIEPILEPTIC ACTIVITY WITH REDUCED SIDE EFFECT | 2007 |
|
RU2440116C2 |
| SYNERGETIC PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF DIABETES MELLITUS | 2002 |
|
RU2311907C2 |
| TREATMENT OF SIDE EFFECTS CAUSED BY ATYPICAL ANTIPSCHOTICS | 2020 |
|
RU2808320C1 |
| NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS FOR TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | 1998 |
|
RU2222330C2 |
| DERIVATIVES OF 7-FLUORO-8-CHLORO-5H-DIBENZO [B, E] [1, 4] DIAZEPINE AND THEIR APPLICATION | 2014 |
|
RU2610169C2 |
| USING CANNABINOIDS COMBINED WITH ANTIPSYCHOTIC DRUG PREPARATION | 2008 |
|
RU2503448C2 |
| PHARMACEUTICAL COMPOSITION ELICITING ANTITUMOR EFFECT WITH REDUCED ADVERSE EFFECTS AND CONTAINING ANTITUMOR AGENT AND DERIVATIVE OF HYDROXAMIC ACID | 1998 |
|
RU2214238C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTIPSYCHOTIC DRUG AND A VMAT2 INHIBITOR, AND THEIR USE | 2015 |
|
RU2757221C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FUNCTIONAL MENTAL DISORDERS | 2016 |
|
RU2667954C2 |
| METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA WITH USING ATYPICAL NEUROLEPTIC COMBINED THERAPY | 2007 |
|
RU2508106C2 |
